As new strains of COVID-19 continue to drive new cases globally, companies and institutions have continued development of interventions for the virus. For example, the FDA granted full approval to Pfizer/BioNTech’s COVID-19 vaccine Comirnaty for the prevention of the disease in individuals 16 years of age and older on August 23, 2021.

Currently, there are over 2,000 COVID-19 clinical trials recruiting patients, with 16% being for vaccines and 84% for therapeutics. By geography, the US has the largest percentage of trials at 20.2%, followed by China and India. A further breakdown can be seen in Figure 1. Four of the top five areas for trial recruitments are states within the US (California, Texas, Florida, and New York), this is likely due to the US having the most COVID-19 cases, with the most cases being in California, Texas, Florida, and New York. Running trials in these locations would raise the success rate of completing these trials, an important factor when considering that the top reason for terminated/suspended/withdrawn COVID-19 clinical trials is low accrual rate, at 17%.

As the US lags based on the number of fully vaccinated citizens compared to other countries such as the United Arab Emirates, Portugal, and Spain, it is expected that unvaccinated patients will drive increased rates of COVID-19. As these cases rise, trends show that the number of recruiting trials will follow, solidifying the US as the top area to run COVID-19 clinical trials with the best chance for a successful trial.